<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: following risks", fill: "#a52a2a"},
{source: "3: following risks", target: "3: financial condition", fill: "#a52a2a"},
{source: "3: financial condition", target: "3: operations would likely suffer", fill: "#a52a2a"},
{source: "3: following risks", target: "7: potential merger", fill: "#014421"},
{source: "7: potential merger", target: "7: activities", fill: "#014421"},
{source: "7: activities", target: "7: satisfy safety requirements", fill: "#014421"},
{source: "7: satisfy safety requirements", target: "7: prove effective", fill: "#014421"},
{source: "7: prove effective", target: "7: undesired clinical", fill: "#014421"},
{source: "7: undesired clinical", target: "7: client decisions", fill: "#014421"},
{source: "7: client decisions", target: "7: particular study perhaps", fill: "#014421"},
{source: "7: particular study perhaps", target: "7: patient enrollment", fill: "#014421"},
{source: "7: patient enrollment", target: "7: investigator recruitment", fill: "#014421"},
{source: "7: investigator recruitment", target: "7: production problems which", fill: "#014421"},
{source: "7: production problems which", target: "7: product withdrawal following market launch", fill: "#014421"},
{source: "7: product withdrawal following market launch", target: "7: manufacturing facilities", fill: "#014421"},
{source: "7: potential merger", target: "8: addition clients may", fill: "#fb607f"},
{source: "8: addition clients may", target: "8: proceed with fewer clinical trials", fill: "#fb607f"},
{source: "8: proceed with fewer clinical trials", target: "8: conduct them without", fill: "#fb607f"},
{source: "8: conduct them without", target: "8: biopharmaceutical services companies", fill: "#fb607f"},
{source: "8: biopharmaceutical services companies", target: "8: reduce costs as", fill: "#fb607f"},
{source: "8: reduce costs as", target: "8: budgetary limits", fill: "#fb607f"},
{source: "8: addition clients may", target: "55: significant", fill: "#cf71af"},
{source: "55: significant", target: "55: client could", fill: "#cf71af"},
{source: "55: client could", target: "55: adversely", fill: "#cf71af"},
{source: "55: adversely", target: "55: financial condition possibly materially", fill: "#cf71af"},
{source: "55: significant", target: "56: five largest clients accounted", fill: "#1cac78"},
{source: "56: five largest clients accounted", target: "56: consolidated service revenue", fill: "#1cac78"},
{source: "56: consolidated service revenue", target: "56: no single client accounted", fill: "#1cac78"},
{source: "56: five largest clients accounted", target: "65: Perceptive Informatics ", fill: "#967117"},
{source: "65: Perceptive Informatics ", target: "65: software products", fill: "#967117"},
{source: "65: software products", target: "65: sophisticated", fill: "#967117"},
{source: "65: sophisticated", target: "65: could contain data design", fill: "#967117"},
{source: "65: could contain data design", target: "65: software errors", fill: "#967117"},
{source: "65: software errors", target: "65: difficult", fill: "#967117"},
{source: "65: Perceptive Informatics ", target: "98: addition while", fill: "#ff8243"},
{source: "98: addition while", target: "98: insurance with respect", fill: "#ff8243"},
{source: "98: insurance with respect", target: "98: insurance also", fill: "#ff8243"},
{source: "98: insurance also", target: "98: deductibles", fill: "#ff8243"},
{source: "98: deductibles", target: "98: coverage limits", fill: "#ff8243"},
{source: "98: addition while", target: "100: service revenue", fill: "#cd5700"},
{source: "100: service revenue", target: "100: operations", fill: "#cd5700"},
{source: "100: operations", target: "100: approximately", fill: "#cd5700"},
{source: "100: approximately", target: "100: consolidated service revenue", fill: "#cd5700"},
{source: "100: consolidated service revenue", target: "100: total consolidated service revenue", fill: "#cd5700"},
{source: "100: service revenue", target: "107: cancellations", fill: "#701c1c"},
{source: "107: cancellations", target: "107: significant", fill: "#701c1c"},
{source: "107: significant", target: "107: fluctuations", fill: "#701c1c"},
{source: "107: cancellations", target: "START_HERE", fill: "#701c1c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Computer Hardware</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parexel">Parexel</a></td>
      <td>Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HM_Revenue_and_Customs">HM Revenue and Customs</a></td>
      <td>Her Majesty's Revenue and Customs (HM Revenue and Customs or HMRC) is a non-ministerial department of the UK Government responsible for the collection of taxes, the payment of some forms of state support, the administration of other regulatory regimes including the national minimum wage and the issuance of national insurance numbers. HMRC was formed by the merger of the Inland Revenue and Her Majesty's Customs and Excise, which took effect on 18 April 2005.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_largest_oil_and_gas_companies_by_revenue">List of largest oil and gas companies by revenue</a></td>
      <td>This is a list of the largest oil and gas companies in the world by yearly total revenue. Total revenue is listed in billions of U.S. dollars.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Difficult_Couple">The Difficult Couple</a></td>
      <td>The Difficult Couple (Chinese: 难夫难妻; pinyin: Nànfū Nànqī), also translated as Die for Marriage, is a 1913 Chinese film. It is known for being the earliest Chinese feature film.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_(song)">Difficult (song)</a></td>
      <td>"Difficult" is the fourth single from French-American recording artist Uffie's debut album, Sex Dreams and Denim Jeans. The single was produced by Uffie's label-mate and friend SebastiAn and was released by Ed Banger Records, Because Music and Elektra Records on October 18, 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Quantum_fluctuation">Quantum fluctuation</a></td>
      <td>In quantum physics, a quantum fluctuation (also known as a vacuum state fluctuation or vacuum fluctuation) is the temporary random change in the amount of energy in a point in space, as prescribed by Werner Heisenberg's uncertainty principle.  They are minute random fluctuations in the values of the fields which represent elementary particles, such as electric and magnetic fields which represent the electromagnetic force carried by photons, W and Z fields which carry the weak force, and gluon fields which carry the strong force.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_fluctuations">Statistical fluctuations</a></td>
      <td>Statistical fluctuations are fluctuations in quantities derived from many identical random processes. They are fundamental and unavoidable.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Thermal_fluctuations">Thermal fluctuations</a></td>
      <td>In statistical mechanics, thermal fluctuations are random deviations of a system from its average state, that occur in a system at equilibrium.  All thermal fluctuations become larger and more frequent as the temperature increases, and likewise they decrease as temperature approaches absolute zero.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fluctuating_asymmetry">Fluctuating asymmetry</a></td>
      <td>Fluctuating asymmetry (FA), is a form of biological asymmetry, along with anti-symmetry and direction asymmetry. Fluctuating asymmetry refers to small, random deviations away from perfect bilateral symmetry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Primordial_fluctuations">Primordial fluctuations</a></td>
      <td>Primordial fluctuations are density variations in the early universe which are considered the seeds of all structure in the universe. Currently, the most widely accepted explanation for their origin is in the context of cosmic inflation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Day_length_fluctuations">Day length fluctuations</a></td>
      <td>The length of the day (LOD), which has increased over the long term of Earth's history due to tidal effects, is also subject to fluctuations on a shorter scale of time. Exact measurements of time by atomic clocks and satellite laser ranging have revealed that the LOD is subject to a number of different changes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Electromagnetic_field">Electromagnetic field</a></td>
      <td>An electromagnetic field (also EM field or EMF) is a classical (i.e. non-quantum) field produced by accelerating electric charges.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Band_of_fluctuation">Band of fluctuation</a></td>
      <td>The band of fluctuation is the range within which the market value of a national currency is permitted to fluctuate by international agreements, or by unilateral decision by the central bank.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PAREXEL INTERNATIONAL CORP      ITEM 1A RISK FACTORS     In addition to other information in this report, the <font color="blue">following risk factors</font>     should be considered <font color="blue">carefully</font> in evaluating our Company and our business</td>
    </tr>
    <tr>
      <td>These <font color="blue">risk factors could</font> cause actual results to <font color="blue">differ from</font> those indicated     by forward-looking statements made in this report, including in the section     of this report entitled “Management’s Discussion and Analysis of Financial     Condition and Results of Operations” and other forward-looking statements     that we may make from time to time</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks</font> occur, our     business, <font color="blue">financial condition</font>, or results of <font color="blue"><font color="blue">operations</font> would likely suffer</font></td>
    </tr>
    <tr>
      <td>THE  LOSS,  MODIFICATION,  OR DELAY OF LARGE OR MULTIPLE CONTRACTS MAY     NEGATIVELY IMPACT OUR FINANCIAL PERFORMANCE     Our <font color="blue">clients <font color="blue">generally</font></font> can terminate their <font color="blue"><font color="blue">contracts with</font> us</font> upon 30 to     60 days notice or can delay the execution of services</td>
    </tr>
    <tr>
      <td>The loss or delay of     a large contract or the loss or delay of <font color="blue">multiple contracts could <font color="blue">adversely</font></font>     affect our operating results, <font color="blue">possibly <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>We have in the past     experienced  contract <font color="blue">cancellation</font>s, which have <font color="blue"><font color="blue">adversely</font> affected</font> our     operating results, including a major <font color="blue">Phase III </font><font color="blue"><font color="blue">cancellation</font> during</font> the first     quarter of <font color="blue">fiscal year</font> 2005</td>
    </tr>
    <tr>
      <td>-15-       _________________________________________________________________    [70]Table of Contents       Clients  terminate  or delay their contracts for a variety of reasons,     including,:       •   merger or <font color="blue">potential merger</font> related <font color="blue">activities</font>;         •   failure of products being tested to <font color="blue">satisfy safety <font color="blue">requirement</font>s</font>;         •   failure of products being tested to <font color="blue">prove <font color="blue">effective</font></font>;         •   products having unexpected or <font color="blue">undesired clinical</font> results;         •   <font color="blue">client decisions</font> to forego a particular study, perhaps for economic     reasons;         •   insufficient <font color="blue">patient enrollment</font> in a study;         •   insufficient <font color="blue">investigator recruitment</font>;         •   <font color="blue">production problems which</font> cause shortages of the product;         •   <font color="blue">product withdrawal following market launch</font>; and         •   shut down of <font color="blue"><font color="blue">manufacturing</font> facilities</font></td>
    </tr>
    <tr>
      <td>In addition, clients may determine to <font color="blue">proceed with fewer <font color="blue"><font color="blue">clinical trial</font>s</font></font> or     <font color="blue">conduct them without</font> the assistance of bio/<font color="blue">pharmaceutical</font> services companies     if  they are trying to <font color="blue">reduce costs as</font> a result of <font color="blue">budgetary limits</font> or     changing  priorities</td>
    </tr>
    <tr>
      <td>These  <font color="blue">factors may</font> cause <font color="blue">such clients</font> to cancel     <font color="blue"><font color="blue">contracts with</font> us</font></td>
    </tr>
    <tr>
      <td>WE FACE INTENSE COMPETITION IN MANY AREAS OF OUR BUSINESS; IF WE DO NOT     COMPETE EFFECTIVELY, OUR BUSINESS WILL BE HARMED     The bio/<font color="blue">pharmaceutical</font> services industry is <font color="blue">highly competitive</font> and we face     <font color="blue">numerous <font color="blue">competitors</font></font> in many areas of our business</td>
    </tr>
    <tr>
      <td>If we fail to compete     <font color="blue"><font color="blue">effective</font>ly</font>, we <font color="blue">may lose clients</font>, which would cause our business to suffer</td>
    </tr>
    <tr>
      <td>We  primarily  compete  against in-house <font color="blue">departments</font> of <font color="blue">pharmaceutical</font>     companies, other full <font color="blue">service <font color="blue">clinical research</font> <font color="blue">organizations</font></font>, or CROs,     small  specialty  CROs, and to a lesser extent, universities, teaching     hospitals, and other <font color="blue">site <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td>and <font color="blue">Pharmaceutical Product Development Inc</font></td>
    </tr>
    <tr>
      <td>In addition, our PCMS business     <font color="blue">competes with</font> a large and fragmented group of <font color="blue">specialty service providers</font>,     including advertising/promotional companies, major consulting firms with     <font color="blue">pharmaceutical</font> industry groups and smaller companies with <font color="blue">pharmaceutical</font>     industry  focus</td>
    </tr>
    <tr>
      <td><font color="blue">Perceptive </font><font color="blue">competes primarily with</font> CROs, information     <font color="blue">technology</font>  companies  and  other  software  companies</td>
    </tr>
    <tr>
      <td>Some of these     <font color="blue">competitors</font>, including the in-house <font color="blue">departments</font> of <font color="blue">pharmaceutical</font> companies,     have greater capital, technical and other <font color="blue">resources than us</font></td>
    </tr>
    <tr>
      <td>In addition,     our  <font color="blue">competitors</font>  that  are  <font color="blue">smaller specialized companies may compete</font>     <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">against us</font> because of their <font color="blue">concentrated size</font> and focus</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">adequately</font>  price  our  contracts or if we experience <font color="blue"><font color="blue">significant</font> cost</font>     overruns, our gross <font color="blue">margins on</font> the <font color="blue">contracts would</font> be reduced and we could     <font color="blue">lose money on contracts</font></td>
    </tr>
    <tr>
      <td>In the past, we have had to commit <font color="blue">unanticipated</font>     resources to complete projects, resulting in lower gross <font color="blue">margins on</font> those     projects</td>
    </tr>
    <tr>
      <td>IF GOVERNMENTAL REGULATION OF THE DRUG, MEDICAL DEVICE AND BIOTECHNOLOGY     INDUSTRY CHANGES, THE NEED FOR OUR SERVICES COULD DECREASE     Governmental  regulation of the drug, medical device and bio<font color="blue">technology</font>     <font color="blue">product <font color="blue">development</font> process</font> is complicated, extensive, and demanding</td>
    </tr>
    <tr>
      <td>A     large  part  of  our  business  involves  assisting <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies through the <font color="blue"><font color="blue">regulatory</font> approval process</font></td>
    </tr>
    <tr>
      <td>Changes in     <font color="blue">regulations</font>, that, for example, streamline procedures or relax approval     standards, could eliminate or reduce the need for our services</td>
    </tr>
    <tr>
      <td>If companies     <font color="blue">regulated by</font> the FDA or similar foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> needed fewer     of our services, we would have fewer business <font color="blue">opportunities</font> and our revenues     would decrease, <font color="blue">possibly <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>-16-       _________________________________________________________________    [71]Table of Contents       In the US, the FDA and the <font color="blue">Congress </font>have attempted to streamline the     <font color="blue">regulatory</font> process by providing for <font color="blue">industry user fees</font> that fund the hiring     of <font color="blue"><font color="blue">additional</font> reviewers</font> and <font color="blue">better <font color="blue">management</font></font> of the <font color="blue">regulatory</font> review     process</td>
    </tr>
    <tr>
      <td>In Europe, <font color="blue">government</font>al <font color="blue">authorities</font> have <font color="blue">approved common standards</font>     for clinical testing of <font color="blue">new drugs throughout</font> the <font color="blue">European Union </font>by adopting     standards for GCP and by making the <font color="blue">clinical trial</font> <font color="blue">application</font> and approval     process more uniform across member states</td>
    </tr>
    <tr>
      <td>The FDA has had GCP in place as a     <font color="blue">regulatory</font> standard and <font color="blue">requirement</font> for new drug approval for many years and     Japan adopted GCP in 1998</td>
    </tr>
    <tr>
      <td>The US, Europe and Japan have <font color="blue">also collaborated</font>     in the 15-year-long <font color="blue">International Conference </font>on Harmonisation, or ICH, the     purpose of which is to eliminate <font color="blue">duplicative</font> or <font color="blue">conflicting</font> <font color="blue">regulations</font> in     the three regions</td>
    </tr>
    <tr>
      <td>The ICH partners have <font color="blue">agreed upon</font> a <font color="blue">common format</font> (the     Common Technical Document) for new drug marketing <font color="blue">application</font>s that reduces     the need to tailor the format to each region</td>
    </tr>
    <tr>
      <td>Such efforts and similar     efforts in the future that streamline the <font color="blue">regulatory</font> process may reduce the     demand for our services</td>
    </tr>
    <tr>
      <td>Parts of our PCMS business <font color="blue">advises clients on how</font> to satisfy <font color="blue">regulatory</font>     standards for <font color="blue">manufacturing</font> and <font color="blue">clinical processes</font> and on other matters     related to the <font color="blue">enforcement</font> of <font color="blue">government</font> <font color="blue">regulations</font> by the FDA and other     <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>Any reduction in levels of review of <font color="blue">manufacturing</font> or     <font color="blue">clinical processes</font> or levels of <font color="blue">regulatory</font> <font color="blue">enforcement</font>, <font color="blue">generally</font>, would     result in fewer business <font color="blue">opportunities</font> for our business in this area</td>
    </tr>
    <tr>
      <td>IF WE FAIL TO COMPLY WITH EXISTING REGULATIONS, OUR REPUTATION AND OPERATING     RESULTS WOULD BE HARMED     Our business is subject to numerous <font color="blue">government</font>al <font color="blue">regulations</font>, primarily     relating to worldwide <font color="blue">pharmaceutical</font> product <font color="blue">development</font> and <font color="blue">regulatory</font>     approval and the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> these     <font color="blue">government</font>al <font color="blue">regulations</font>, it could result in the <font color="blue">termination</font> of our ongoing     research,   <font color="blue">development</font>  or  sales  and  marketing  projects,  or  the     <font color="blue">disqualification</font> of data for submission to <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We also     could be <font color="blue">barred from providing <font color="blue">clinical trial</font> services</font> in the future or     could  be subjected to fines</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">consequences</font> would harm our     reputation, our prospects for future work and our operating results</td>
    </tr>
    <tr>
      <td>In     addition, we may have to repeat research or <font color="blue">redo trials</font></td>
    </tr>
    <tr>
      <td>If we are required     to repeat research or <font color="blue">redo trials</font>, we may be <font color="blue">contractually</font> required to do so     <font color="blue">at no further cost</font> to our clients, but at substantial cost to us</td>
    </tr>
    <tr>
      <td>WE MAY LOSE BUSINESS OPPORTUNITIES AS A RESULT OF HEALTH CARE REFORM AND THE     EXPANSION OF MANAGED-CARE ORGANIZATIONS     Numerous <font color="blue">government</font>s, including the US <font color="blue">government</font> and <font color="blue">government</font>s outside     of the US have <font color="blue">undertaken efforts</font> to <font color="blue">control growing health care costs</font>     through legislation, regulation and <font color="blue">voluntary agreements with medical care</font>     providers and <font color="blue">drug companies</font></td>
    </tr>
    <tr>
      <td>If these efforts are successful, drug, medical     device and bio<font color="blue">technology</font> companies may react by spending less on research     and  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If this were to occur, we would have fewer business     <font color="blue">opportunities</font> and our <font color="blue">revenues could decrease</font>, <font color="blue">possibly <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>In     addition, new laws or <font color="blue">regulations</font> may create a risk of <font color="blue">liability</font>, increase     our costs or limit our <font color="blue">service offerings</font></td>
    </tr>
    <tr>
      <td>For  instance,  in  the past the US <font color="blue">Congress </font>has <font color="blue">entertained several</font>     <font color="blue">comprehensive <font color="blue"><font color="blue">health care reform</font> proposals</font></font></td>
    </tr>
    <tr>
      <td>The proposals were <font color="blue">generally</font>     intended to <font color="blue">expand health care coverage</font> for the uninsured and reduce the     growth of <font color="blue">total health care expenditures</font></td>
    </tr>
    <tr>
      <td><font color="blue">While the US <font color="blue">Congress </font></font>has not     yet adopted any comprehensive reform proposals, members of <font color="blue">Congress </font>may     raise  similar  proposals  in the future</td>
    </tr>
    <tr>
      <td>We are unable to predict the     likelihood that <font color="blue"><font color="blue"><font color="blue">health care reform</font> proposals</font> will</font> be <font color="blue">enacted into law</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue"><font color="blue">health care reform</font> proposals</font>, the expansion of managed-care     <font color="blue">organizations</font> in the <font color="blue">health care market</font> and managed-care <font color="blue">organizations</font>’     efforts to cut costs by limiting expenditures on <font color="blue">pharmaceutical</font>s and medical     devices could result in <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and medical device     <font color="blue">companies spending less on research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If this were to occur,     we would have fewer business <font color="blue">opportunities</font> and our <font color="blue">revenues could decrease</font>,     <font color="blue">possibly <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>IF WE DO NOT KEEP PACE WITH RAPID TECHNOLOGICAL CHANGES, OUR PRODUCTS AND     SERVICES  MAY  BECOME  LESS COMPETITIVE OR OBSOLETE, ESPECIALLY IN OUR     PERCEPTIVE BUSINESS     The bio<font color="blue">technology</font>, <font color="blue">pharmaceutical</font> and medical device industries <font color="blue">generally</font>,     and  <font color="blue"><font color="blue">clinical research</font> <font color="blue">specifically</font></font>, are subject to <font color="blue">increasingly rapid</font>     <font color="blue">technological</font> changes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> or <font color="blue">others might</font> develop <font color="blue">technologies</font>,     products or services that are more <font color="blue">effective</font> or <font color="blue">commercially attractive than</font>     our current or future <font color="blue">technologies</font>, products or services, or render our     <font color="blue">technologies</font>,  products  or  <font color="blue">services less competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>If     <font color="blue">competitors</font> introduce superior <font color="blue">technologies</font>, products or services and we     cannot  make  <font color="blue">enhancements</font>  to our <font color="blue">technologies</font>, products and services     <font color="blue">necessary</font> to <font color="blue">remain competitive</font>, our <font color="blue">competitive position would</font> be harmed</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">compete successfully</font>, we <font color="blue">may lose clients</font> or be unable     to attract new clients, <font color="blue">which could</font> lead to a decrease in our revenue</td>
    </tr>
    <tr>
      <td>-17-       _________________________________________________________________    [72]Table of Contents       BECAUSE WE DEPEND ON A SMALL NUMBER OF INDUSTRIES AND CLIENTS FOR ALL OF OUR     BUSINESS, THE LOSS OF BUSINESS FROM A SIGNIFICANT CLIENT COULD HARM OUR     BUSINESS, REVENUE AND FINANCIAL CONDITION     The loss of, or a material reduction in the business of, a <font color="blue">significant</font>     <font color="blue">client could</font> cause a substantial decrease in our revenue and <font color="blue">adversely</font>     affect our business and <font color="blue">financial condition</font>, <font color="blue">possibly <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>In both     <font color="blue">fiscal year</font> 2006 and <font color="blue">fiscal year</font> 2005, our <font color="blue">five largest clients accounted</font>     for 25prca of our <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> and <font color="blue">no single client accounted</font>     for 10prca or more of <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font></td>
    </tr>
    <tr>
      <td>We expect that a small     number of <font color="blue">clients <font color="blue">will continue</font></font> to represent a <font color="blue">significant</font> part of our     revenue</td>
    </tr>
    <tr>
      <td>Our <font color="blue">contracts with</font> these <font color="blue">clients <font color="blue">generally</font></font> can be <font color="blue">terminated on</font>     short notice</td>
    </tr>
    <tr>
      <td>We have in the past experienced <font color="blue">contract <font color="blue">cancellation</font>s with</font>     <font color="blue">significant</font> clients</td>
    </tr>
    <tr>
      <td>IF OUR PERCEPTIVE BUSINESS IS UNABLE TO MAINTAIN CONTINUOUS, EFFECTIVE,     RELIABLE  AND  SECURE OPERATION OF ITS COMPUTER HARDWARE, SOFTWARE AND     INTERNET APPLICATIONS AND RELATED TOOLS AND FUNCTIONS, ITS BUSINESS WILL BE     HARMED     Our  <font color="blue">Perceptive </font> Informatics  business  involves collecting, managing,     <font color="blue">manipulating</font> and analyzing large amounts of data, and communicating data via     the Internet</td>
    </tr>
    <tr>
      <td>In our <font color="blue">Perceptive </font>Informatics business, we <font color="blue">depend on</font> the     continuous, <font color="blue">effective</font>, reliable and <font color="blue">secure operation</font> of <font color="blue">computer hardware</font>,     software, networks, telecommunication networks, Internet servers and related     <font color="blue">infrastructure</font></td>
    </tr>
    <tr>
      <td>If the hardware or software <font color="blue">malfunctions</font> or access to data     by  internal  research  personnel or customers through <font color="blue">the Internet </font>is     <font color="blue">interrupted</font>, our <font color="blue">Perceptive </font>Informatics business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In addition,     any <font color="blue">sustained disruption</font> in Internet <font color="blue">access provided by third parties could</font>     <font color="blue">adversely</font> impact our <font color="blue">Perceptive </font>Informatics business</td>
    </tr>
    <tr>
      <td>Although the computer and <font color="blue">communications</font> hardware used in our <font color="blue">Perceptive </font>    Informatics business is <font color="blue">protected through physical</font> and <font color="blue">software safeguards</font>,     it is <font color="blue">still vulnerable</font> to fire, storm, flood, power loss, earthquakes,     tele<font color="blue">communications</font> failures, physical or software break-ins, and similar     events</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Perceptive </font>Informatics <font color="blue">software products</font> are     complex and <font color="blue">sophisticated</font>, and could contain data, design or <font color="blue">software errors</font>     that  could be <font color="blue">difficult</font> to detect and correct</td>
    </tr>
    <tr>
      <td>If <font color="blue">Perceptive </font>fails to     maintain and further develop the <font color="blue">necessary</font> computer capacity and data to     support the needs of our <font color="blue">Perceptive </font>Informatics customers, it could result     in a loss of or a delay in revenue and <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO ATTRACT SUITABLE WILLING VOLUNTEERS FOR THE CLINICAL     TRIALS OF OUR CLIENTS, OUR CRS BUSINESS MAY SUFFER     One of the <font color="blue">factors on which</font> our CRS business competes is the ability to     <font color="blue">recruit patients</font> for the <font color="blue">clinical studies</font> we are managing</td>
    </tr>
    <tr>
      <td>These clinical     trials  rely upon the <font color="blue">ready accessibility</font> and <font color="blue">willing participation</font> of     <font color="blue">volunteer subjects</font></td>
    </tr>
    <tr>
      <td>These subjects <font color="blue">generally</font> include <font color="blue">volunteers from</font> the     <font color="blue">communities</font> in which the studies are conducted</td>
    </tr>
    <tr>
      <td>Although to date these     <font color="blue">communities</font> have provided a substantial pool of potential subjects for     research studies, there may not be enough patients available with the traits     <font color="blue">necessary</font> to conduct the studies</td>
    </tr>
    <tr>
      <td>If multiple <font color="blue">organizations</font> are conducting similar studies and     competing for patients, it <font color="blue">could also</font> make our <font color="blue">recruitment efforts</font> more     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>If we were unable to <font color="blue">attract suitable</font> and <font color="blue">willing volunteers on</font> a     <font color="blue">consistent</font>  basis, it would have an adverse effect on the trials being     <font color="blue">managed by</font> our CRS business, <font color="blue">which could</font> have a material adverse effect on     our CRS business</td>
    </tr>
    <tr>
      <td>IF WE CANNOT RETAIN OUR HIGHLY QUALIFIED MANAGEMENT AND TECHNICAL PERSONNEL,     OUR BUSINESS WOULD BE HARMED     We rely on the expertise of our Chairman and Chief Executive Officer, Josef     H  von  <font color="blue"><font color="blue">Rickenbach </font> </font>and it would be <font color="blue">difficult</font> and expensive to find a     qualified  <font color="blue">replacement</font>  with the level of specialized knowledge of our     products and services and the bio/<font color="blue">pharmaceutical</font> services industry</td>
    </tr>
    <tr>
      <td>We are a     party to an <font color="blue">employment agreement with</font> Mr</td>
    </tr>
    <tr>
      <td>von Rickenbach, which may be     <font color="blue">terminated by us</font> or Mr</td>
    </tr>
    <tr>
      <td>von <font color="blue">Rickenbach </font>upon notice to the other party</td>
    </tr>
    <tr>
      <td>In addition, in order to compete <font color="blue"><font color="blue">effective</font>ly</font>, we <font color="blue">must attract</font> and maintain     qualified  sales,  <font color="blue">professional</font>,  scientific,  and technical operating     personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for these skilled personnel, <font color="blue">particularly</font> those with     a medical degree, a Ph</td>
    </tr>
    <tr>
      <td>We may not be     successful in attracting or retaining <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>-18-       _________________________________________________________________    [73]Table of Contents       WE MAY HAVE SUBSTANTIAL EXPOSURE TO PAYMENT OF PERSONAL INJURY CLAIMS AND     MAY NOT HAVE ADEQUATE INSURANCE TO COVER SUCH CLAIMS     Our CRS business <font color="blue">primarily involves</font> the testing of <font color="blue">experimental drugs</font> and     medical devices on consenting human volunteers pursuant to a <font color="blue">study protocol</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">research involves</font> a risk of <font color="blue">liability</font> for <font color="blue">personal injury</font> or death     to patients who <font color="blue">participate</font> in the study or who use a <font color="blue">product approved by</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font> after the <font color="blue">clinical research</font> has concluded, due to,     among other reasons, possible unforeseen adverse side effects or improper     <font color="blue">administration</font> of the drug or device <font color="blue">by physicians</font></td>
    </tr>
    <tr>
      <td>In some cases, these     patients are <font color="blue">already seriously ill</font> and are at risk of <font color="blue">further illness</font> or     death</td>
    </tr>
    <tr>
      <td>In order to mitigate the risk of <font color="blue">liability</font>, we seek to include <font color="blue">indemnity</font>     provisions in our <font color="blue">Clinical Research Services </font><font color="blue">contracts with</font> clients and with     <font color="blue">investigators</font></td>
    </tr>
    <tr>
      <td>However, we are not able to include <font color="blue">indemnity</font> provisions in     all of our contracts</td>
    </tr>
    <tr>
      <td>The <font color="blue">indemnity</font> provisions we include in these contracts     would not cover our exposure if:       •   we had to pay damages or <font color="blue">incur defense costs</font> in <font color="blue">connection with</font> a     claim that is outside the scope of an <font color="blue">indemnity</font>; or         •   a <font color="blue">client failed</font> to <font color="blue">indemnify us</font> in <font color="blue">accordance with</font> the terms of an     <font color="blue">indemnity</font> agreement because it did not have the <font color="blue">financial ability</font> to fulfill     its <font color="blue">indemnification obligation</font> or for any other reason</td>
    </tr>
    <tr>
      <td>We  also  carry insurance to cover our risk of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>However, our     insurance is subject to <font color="blue">deductibles</font> and <font color="blue">coverage limits</font> and may not be     adequate to cover claims</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">liability</font> coverage is expensive</td>
    </tr>
    <tr>
      <td>In     the future, we may not be able to maintain or obtain <font color="blue">liability</font> insurance on     reasonable terms, at a reasonable cost, or in <font color="blue">sufficient amounts</font> to protect     <font color="blue">us against losses due</font> to claims</td>
    </tr>
    <tr>
      <td>In March 2006, we conducted a Phase I <font color="blue"><font color="blue">clinical trial</font> on behalf</font> of TeGenero     AG, a German <font color="blue">pharmaceutical</font> company</td>
    </tr>
    <tr>
      <td>During the trial, six <font color="blue">participants</font>     experienced adverse reactions <font color="blue">to the TeGenero </font>compound being tested</td>
    </tr>
    <tr>
      <td>Through     June 30, 2006, we have expensed <font color="blue">approximately</font> dlra1dtta2 million in <font color="blue">legal fees</font> and     other <font color="blue">incremental costs</font> in <font color="blue">connection with</font> the incident</td>
    </tr>
    <tr>
      <td>To date, none of     the <font color="blue">participants</font> in the <font color="blue">clinical trial</font> have <font color="blue">filed suit <font color="blue">against us</font></font></td>
    </tr>
    <tr>
      <td>We carry     insurance to cover risks such as this, but our insurance is subject to     <font color="blue">deductibles</font> and <font color="blue">coverage limits</font> and may not be adequate to cover claims     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>While we believe that TeGenero is responsible to <font color="blue">indemnify us</font>     <font color="blue">with respect</font> to claims related to this matter, TeGenero filed for <font color="blue">insolvency</font>     in July 2006, which likely will limit any <font color="blue">recovery by us from them</font></td>
    </tr>
    <tr>
      <td>In     addition, while TeGenero carried insurance <font color="blue">with respect</font> to this type of     matter, this <font color="blue">insurance also</font> is subject to <font color="blue">deductibles</font> and <font color="blue">coverage limits</font></td>
    </tr>
    <tr>
      <td>OUR BUSINESS IS SUBJECT TO INTERNATIONAL ECONOMIC, POLITICAL, AND OTHER     RISKS THAT COULD NEGATIVELY AFFECT OUR RESULTS OF OPERATIONS OR FINANCIAL     POSITION     We <font color="blue">provide most</font> of our <font color="blue">services on</font> a <font color="blue">worldwide basis</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">service revenue</font>     from  non-US  <font color="blue">operations</font>  represented  <font color="blue">approximately</font>  64dtta6prca of total     <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for the <font color="blue">fiscal year</font> ended June 30, 2006 and     <font color="blue">approximately</font> 62dtta7prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for the fiscal     year  ended June 30, 2005</td>
    </tr>
    <tr>
      <td>More <font color="blue">specifically</font>, our <font color="blue">service revenue</font> from     <font color="blue">operations</font> in the <font color="blue">United Kingdom </font>represented <font color="blue">approximately</font> 17dtta0prca of total     <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for the <font color="blue">fiscal year</font> ended June 30, 2006 and     <font color="blue">approximately</font> 19dtta7prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for the fiscal     year ended June 30, 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">service revenue</font> from <font color="blue">operations</font> in <font color="blue">Germany     </font>represented <font color="blue">approximately</font> 20dtta2prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for     the  fiscal  year ended June 30, 2006 and <font color="blue">approximately</font> 18dtta6prca of total     <font color="blue">consolidated</font>  <font color="blue">service revenue</font> for the <font color="blue">fiscal year</font> ended June 30, 2005</td>
    </tr>
    <tr>
      <td>Accordingly, our business is subject to <font color="blue">risks associated with</font> doing business     <font color="blue">internationally</font>, including:       •   changes in a specific country’s or region’s political or economic     <font color="blue">conditions</font>, including Western Europe, in particular;         •   potential negative <font color="blue">consequences</font> from changes in tax laws <font color="blue">affecting</font> our     ability to repatriate profits;         •   <font color="blue">difficult</font>y in staffing and managing widespread <font color="blue">operations</font>;         •   unfavorable labor <font color="blue">regulations</font> applicable to its European or other     international <font color="blue">operations</font>;         •   changes in <font color="blue">foreign currency exchange rates</font>; and          •     longer  <font color="blue">payment cycles</font> of <font color="blue">foreign customers</font> and <font color="blue">difficult</font>y of     <font color="blue">collecting receivables</font> in <font color="blue">foreign <font color="blue">jurisdictions</font></font></td>
    </tr>
    <tr>
      <td>-19-       _________________________________________________________________    [74]Table of Contents       OUR OPERATING RESULTS HAVE FLUCTUATED BETWEEN QUARTERS AND YEARS AND MAY     CONTINUE TO FLUCTUATE IN THE FUTURE, WHICH COULD AFFECT THE PRICE OF OUR     COMMON STOCK     Our quarterly and annual operating results have varied and <font color="blue">will continue</font> to     vary in the future as a result of a variety of factors</td>
    </tr>
    <tr>
      <td>For example, our     income  from  <font color="blue">operations</font>  totaled  dlra5dtta0 million  for the quarter ended     <font color="blue">September </font>30, 2005, dlra10dtta6 million for the quarter ended <font color="blue">December </font>31, 2005,     dlra11dtta2 million for the quarter ended March 31, 2006 and dlra13dtta1 million for the     quarter ended June 30, 2006</td>
    </tr>
    <tr>
      <td>Factors that cause these <font color="blue">variations</font> include:       •   the level of new business <font color="blue">authorizations</font> in a <font color="blue">particular quarter</font> or     year;         •   the timing of the <font color="blue">initiation</font>, progress, or <font color="blue">cancellation</font> of <font color="blue">significant</font>     projects;         •   <font color="blue">exchange rate <font color="blue">fluctuations</font> between quarters</font> or years;         •   <font color="blue">restructuring charges</font>;         •   the mix of <font color="blue">services offered</font> in a <font color="blue">particular quarter</font> or year;         •   the timing of the opening of new offices;         •   costs and the related <font color="blue">financial impact</font> of <font color="blue">acquisitions</font>;         •   the timing of <font color="blue">internal expansion</font>;          •     the  timing  and  amount of <font color="blue">costs associated with integrating</font>     <font color="blue">acquisitions</font>;         •   the timing and amount of <font color="blue">startup costs incurred</font> in <font color="blue">connection with</font> the     <font color="blue">introduction</font> of new products, services or <font color="blue">subsidiaries</font>; and         •   the <font color="blue">dollar amount</font> of changes in <font color="blue">contract scope finalized during</font> a     <font color="blue">particular period</font></td>
    </tr>
    <tr>
      <td>Many of these factors, such as the timing of <font color="blue">cancellation</font>s of <font color="blue">significant</font>     projects and <font color="blue">exchange rate <font color="blue">fluctuations</font> between quarters</font> or years, are     beyond our control</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>60-65prca of our operating costs are fixed in the short term with     a <font color="blue">significant</font> portion of those costs related to personnel</td>
    </tr>
    <tr>
      <td>As a result, the effect on our revenues     of the timing of the completion, delay or loss of contracts, or the progress     of client projects, could cause our operating results to <font color="blue">vary <font color="blue">substantially</font></font>     between reporting periods</td>
    </tr>
    <tr>
      <td>If  our  operating results do not match the <font color="blue">expectations</font> of securities     analysts and investors, the <font color="blue">trading price</font> of our <font color="blue"><font color="blue">common stock</font> will likely</font>     decrease</td>
    </tr>
    <tr>
      <td>OUR REVENUE AND EARNINGS ARE EXPOSED TO EXCHANGE RATE FLUCTUATIONS     <font color="blue">Approximately </font>64dtta6prca of our total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> for the fiscal     year ended June 30, 2006 and <font color="blue">approximately</font> 62dtta7prca of our total <font color="blue">consolidated</font>     <font color="blue">service revenue</font> for the <font color="blue">fiscal year</font> ended June 30, 2005 were from non-US     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial statements</font> are <font color="blue">denominated</font> in US dollars</td>
    </tr>
    <tr>
      <td>As a     result, changes in <font color="blue">foreign currency exchange rates</font> could have and have had a     <font color="blue">significant</font> effect on our operating results</td>
    </tr>
    <tr>
      <td>For example, as a result of     year-over-year foreign currency fluctuation, <font color="blue">service revenue</font> for <font color="blue">fiscal year</font>     2006 was negatively impacted by <font color="blue">approximately</font>, dlra18dtta7 million as compared to     <font color="blue">fiscal year</font> 2005</td>
    </tr>
    <tr>
      <td>Exchange rate <font color="blue">fluctuations</font> between local currencies and     the US dollar create risk in <font color="blue">several ways</font>, including:       •   <font color="blue">Foreign Currency Translation Risk</font></td>
    </tr>
    <tr>
      <td>The revenue and expenses of our     foreign <font color="blue">operations</font> are <font color="blue">generally</font> <font color="blue">denominated</font> in local currencies, primarily     the British pound and the Euro, and then are translated into US dollars     for financial reporting purposes</td>
    </tr>
    <tr>
      <td>For the <font color="blue">fiscal year</font> ended June 30, 2006,     <font color="blue">approximately</font> 17dtta0prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> was <font color="blue">denominated</font> in     British pounds and <font color="blue">approximately</font> 37dtta0prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font>     was <font color="blue">denominated</font> in Euros</td>
    </tr>
    <tr>
      <td>For the <font color="blue">fiscal year</font> ended June 30, 2005,     <font color="blue">approximately</font> 19dtta7prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font> was <font color="blue">denominated</font> in     British pounds and <font color="blue">approximately</font> 34dtta2prca of total <font color="blue"><font color="blue">consolidated</font> <font color="blue">service revenue</font></font>     was <font color="blue">denominated</font> in Euros</td>
    </tr>
    <tr>
      <td>Accordingly, changes in <font color="blue">exchange rates between</font>     foreign currencies and the US <font color="blue">dollar will affect</font> the <font color="blue">translation</font> of     foreign results into US dollars for purposes of reporting our <font color="blue">consolidated</font>     results</td>
    </tr>
    <tr>
      <td>We may be subjected to foreign     currency <font color="blue">transaction</font> risk when our foreign <font color="blue">subsidiaries</font> enter into contracts     or incur liabilities <font color="blue">denominated</font> in a currency other than the foreign     <font color="blue">subsidiaries</font> functional (local) currency</td>
    </tr>
    <tr>
      <td>To the extent we are unable to     shift the effects of currency <font color="blue">fluctuations</font> to the clients, foreign exchange     <font color="blue">fluctuations</font> as a result of <font color="blue">foreign currency exchange losses could</font> have a     material adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we try to limit these risks through exchange rate fluctuation     provisions stated in our service contracts, or <font color="blue">by hedging <font color="blue">transaction</font> risk</font>     with  foreign  currency  exchange  contracts,  we may still experience     <font color="blue">fluctuations</font> in financial results from our <font color="blue">operations</font> outside of the US,     and  may not be able to favorably reduce the currency <font color="blue">transaction</font> risk     associated with our service contracts</td>
    </tr>
    <tr>
      <td>OUR BUSINESS HAS EXPERIENCED SUBSTANTIAL EXPANSION IN THE PAST AND SUCH     EXPANSION  AND  ANY FUTURE EXPANSION COULD STRAIN OUR RESOURCES IF NOT     PROPERLY MANAGED     We  have expanded our business <font color="blue">substantially</font> in the past</td>
    </tr>
    <tr>
      <td>Future rapid     <font color="blue">expansion could</font> strain our operational, human and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>In     order to <font color="blue">manage expansion</font>, we must:       •   continue to improve operating, <font color="blue">administrative</font>, and information     systems;         •   <font color="blue">accurately predict future personnel</font> and resource needs to <font color="blue">meet client</font>     <font color="blue">contract commitments</font>;         •   track the progress of <font color="blue">ongoing client</font> projects; and          •     attract and retain qualified <font color="blue">management</font>, sales, <font color="blue">professional</font>,     scientific and technical operating personnel</td>
    </tr>
    <tr>
      <td>If we do not take these actions and are not able to manage the expanded     business, the expanded business may be <font color="blue">less successful than</font> anticipated, and     we  may  be  required to <font color="blue">allocate <font color="blue">additional</font> resources</font> to the expanded     business, which we would have <font color="blue">otherwise allocated</font> to another part of our     business</td>
    </tr>
    <tr>
      <td>We  may  face  <font color="blue">additional</font>  risks  in expanding our foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Specifically, we may find it <font color="blue">difficult</font> to:       •   <font color="blue">assimilate <font color="blue">differences</font></font> in foreign business practices, exchange rates     and <font color="blue">regulatory</font> <font color="blue">requirement</font>s;         •   operate <font color="blue">amid political</font> and <font color="blue">economic instability</font>;         •   hire and retain <font color="blue">qualified personnel</font>; and         •   overcome language, tariff and other barriers</td>
    </tr>
    <tr>
      <td>WE MAY MAKE ACQUISITIONS IN THE FUTURE, WHICH MAY LEAD TO DISRUPTIONS TO OUR     ONGOING BUSINESS     We  have made a number of <font color="blue">acquisitions</font> and <font color="blue">will continue</font> to <font color="blue">review new</font>     acquisition <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully integrate</font> an     acquired company, the <font color="blue">acquisition could lead</font> to <font color="blue">disruptions</font> to our business</td>
    </tr>
    <tr>
      <td>The success of an acquisition will depend upon, among other things, our     ability to:       •   assimilate the <font color="blue">operations</font> and services or products of the acquired     company;         •   integrate acquired personnel;         •   retain and <font color="blue">motivate key employees</font>;         •   retain customers;         •   identify and <font color="blue">manage risks facing</font> the acquired company; and         •   minimize the diversion of <font color="blue">management</font>’s attention from other business     concerns</td>
    </tr>
    <tr>
      <td>-21-       _________________________________________________________________    [76]Table of Contents       Acquisitions  of  foreign companies may also involve <font color="blue">additional</font> risks,     including  <font color="blue">assimilating</font>  <font color="blue">differences</font> in foreign business practices and     overcoming language and cultural barriers</td>
    </tr>
    <tr>
      <td>In the event that the <font color="blue">operations</font> of an acquired business do not meet our     performance <font color="blue">expectations</font>, we may have to <font color="blue">restructure</font> the acquired business     or  write-off  the  value of some or all of the assets of the acquired     business</td>
    </tr>
    <tr>
      <td>OUR EFFECTIVE INCOME TAX RATE MAY FLUCTUATE FROM QUARTER-TO-QUARTER, WHICH     MAY AFFECT EARNINGS AND EARNINGS PER SHARE     Our quarterly <font color="blue">effective</font> income tax rate is <font color="blue">influenced by</font> our projected     <font color="blue">profitability</font> in the <font color="blue">various taxing <font color="blue">jurisdictions</font></font> in which we operate</td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">distribution</font> of profits and <font color="blue">losses among taxing <font color="blue">jurisdictions</font></font>     may have a <font color="blue">significant</font> impact on our <font color="blue">effective</font> income tax rate, which in     turn could have a material adverse effect on our net income and <font color="blue">earnings per</font>     share</td>
    </tr>
    <tr>
      <td>Factors that affect the <font color="blue">effective</font> income tax rate include, but are     not limited to:       •   the <font color="blue">requirement</font> to <font color="blue">exclude from</font> our quarterly worldwide <font color="blue">effective</font>     <font color="blue">income tax calculations losses</font> in <font color="blue">jurisdictions</font> where <font color="blue">no tax benefit</font> can be     recognized;         •   actual and projected full <font color="blue">year pretax income</font>;         •   changes in tax laws in the <font color="blue">various taxing <font color="blue">jurisdictions</font></font>;         •   <font color="blue">audits by</font> the taxing <font color="blue">authorities</font>; and         •   the <font color="blue">establishment</font> of <font color="blue">valuation allowances against deferred tax assets</font>     if it is determined that it is more <font color="blue">likely than</font> not that <font color="blue">future tax benefits</font>     will not be realized</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our <font color="blue">effective</font> income tax rate could cause <font color="blue">fluctuations</font> in     our earnings and <font color="blue">earnings per</font> share, which can affect our stock price</td>
    </tr>
    <tr>
      <td>OUR CORPORATE GOVERNANCE STRUCTURE, INCLUDING PROVISIONS OF OUR ARTICLES OF     ORGANIZATION,  AND  BY-LAWS,  AND  OUR  SHAREHOLDER  RIGHTS  PLAN, AND     MASSACHUSETTS LAW MAY DELAY OR PREVENT A CHANGE IN CONTROL OR MANAGEMENT     THAT STOCKHOLDERS MAY CONSIDER DESIRABLE     Provisions of our articles of organization, by-laws and our <font color="blue">shareholder</font>     rights plan, as well as provisions <font color="blue">of Massachusetts </font>law, may enable our     <font color="blue">management</font> to <font color="blue">resist acquisition</font> of us by a <font color="blue">third party</font>, or <font color="blue">may discourage</font> a     <font color="blue">third party</font> from acquiring us</td>
    </tr>
    <tr>
      <td>These provisions include the following:       •   we have divided our board of <font color="blue">directors</font> into three classes that serve     staggered three-year terms;          •     we  are subject to Section 8dtta06 of the Massachusetts Business     Corporation  Law  which provides that <font color="blue">directors</font> may only be <font color="blue">removed by</font>     <font color="blue">stockholders</font> for cause, vacancies in our board of <font color="blue">directors</font> may only be     <font color="blue">filled by</font> a vote of our board of <font color="blue">directors</font> and the number of <font color="blue">directors</font> may     be fixed only by our board of <font color="blue">directors</font>;         •   we are subject to Chapter 110F of the <font color="blue">Massachusetts General Laws </font>which     limits  our  ability  to  engage in business <font color="blue">combinations with certain</font>     interested <font color="blue">stockholders</font>;         •   our <font color="blue">stockholders</font> are limited in their ability to call or introduce     <font color="blue">proposals at stockholder meetings</font>; and         •   our <font color="blue">shareholder</font> rights plan would cause a <font color="blue">proposed acquirer</font> of 20prca or     more  of  our <font color="blue">outstanding shares</font> of <font color="blue">common stock</font> to suffer <font color="blue">significant</font>     dilution</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font> have the effect of delaying, deferring, or preventing     a change in control of us or a change in our <font color="blue">management</font> that <font color="blue">stockholders</font>     may consider favorable or <font color="blue">beneficial</font></td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">could also</font> discourage     proxy  contests  and  make it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> to elect     <font color="blue">directors</font> and take other <font color="blue">corporate actions</font></td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">could also</font>     limit the price that investors might be willing to pay in the future for     shares of our stock</td>
    </tr>
    <tr>
      <td>-22-       _________________________________________________________________    [77]Table of Contents       In addition, our board of <font color="blue">directors</font> may issue <font color="blue">preferred stock</font> in the future     <font color="blue">without stockholder approval</font></td>
    </tr>
    <tr>
      <td>If our board of <font color="blue">directors</font> issues preferred     stock, the holders of <font color="blue">common stock</font> would be subordinate to the rights of the     holders of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font>’ ability to issue the     <font color="blue">preferred stock</font> could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire,     or discourage a <font color="blue">third party</font> from acquiring, a majority of our stock</td>
    </tr>
    <tr>
      <td>OUR STOCK PRICE HAS BEEN AND MAY IN THE FUTURE BE VOLATILE, WHICH COULD LEAD     TO LOSSES BY INVESTORS     The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">fluctuated widely</font> in the past and     <font color="blue">may continue</font> to do so in the future</td>
    </tr>
    <tr>
      <td>On August 30, 2006, the closing sale     price of our <font color="blue">common stock</font> on the <font color="blue">NASDAQ Global Select Market </font>was dlra33dtta48 per     share</td>
    </tr>
    <tr>
      <td>During the period from July 1, 2004 to June 30, 2006, the closing     price of our <font color="blue">common stock</font> ranged from a high of dlra30dtta44 per share to a low of     dlra17dtta28 per share</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>in our <font color="blue">common stock</font> must be willing to bear the     risk of such <font color="blue">fluctuations</font> in stock price and the risk that the value of an     <font color="blue">investment</font> in our <font color="blue"><font color="blue">stock could</font> decline</font></td>
    </tr>
    <tr>
      <td>Our stock price can be affected by quarter-to-quarter <font color="blue">variations</font> in a number     of factors including, but not limited to:       •   operating results;         •   earnings estimates <font color="blue">by analysts</font>;         •   market <font color="blue">conditions</font> in the industry;         •   prospects of <font color="blue">health care reform</font>;         •   changes in <font color="blue">government</font> <font color="blue">regulations</font>;         •   general economic <font color="blue">conditions</font>, and         •   our <font color="blue">effective</font> income tax rate</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has from time to time experienced <font color="blue">significant</font>     price  and  volume  <font color="blue">fluctuations</font> that are not related to the operating     performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These market <font color="blue">fluctuations</font> may <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Since our <font color="blue">common stock</font> has     traded in the past at a <font color="blue">relatively</font> high price-earnings multiple, due in part     to analysts’ <font color="blue">expectations</font> of <font color="blue">earnings growth</font>, the price of the <font color="blue">stock could</font>     quickly and <font color="blue">substantially</font> decline as a result of even a <font color="blue">relatively</font> small     shortfall in <font color="blue">earnings from</font>, or a change in, analysts’ <font color="blue">expectations</font></td>
    </tr>
  </tbody>
</table>